Mink Therapeutics Q4 2023 Earnings Report
Key Takeaways
MiNK Therapeutics reported its Q4 and full-year 2023 financial results, highlighting the progression of its lead program, agenT-797, into a Phase 2 study in gastroesophageal cancers. The company ended the year with a cash balance of $3.4 million and reported a net loss for the year of $22.5 million, or $0.65 per share.
Advanced allogeneic iNKT cell programs, contributing to clinical data.
Expanded pipeline and solidified partnerships, including a research agreement with ImmunoScape.
Progressed agenT-797 into a Phase 2 study in gastroesophageal cancers.
Anticipate sharing initial trial data later this year.
Mink Therapeutics
Mink Therapeutics
Forward Guidance
MiNK Therapeutics is focused on advancing its lead program, agenT-797, particularly in indications with promising proof-of-concept data and anticipates sharing initial trial data later this year.